Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Brokerages

Perspective Therapeutics, Inc. (NYSE:CATXGet Free Report) has been given a consensus recommendation of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $1.90.

A number of research analysts have commented on the stock. Royal Bank of Canada assumed coverage on shares of Perspective Therapeutics in a research note on Tuesday, May 14th. They set an “outperform” rating and a $3.00 price target for the company. Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Cantor Fitzgerald assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, May 9th. They set an “overweight” rating for the company. B. Riley lifted their target price on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st.

Get Our Latest Stock Report on CATX

Insider Activity

In related news, Director Lori A. Woods purchased 34,246 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was acquired at an average price of $1.46 per share, with a total value of $49,999.16. Following the completion of the acquisition, the director now directly owns 1,553,984 shares in the company, valued at approximately $2,268,816.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Robert F. Williamson III purchased 30,031 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was acquired at an average price of $1.33 per share, with a total value of $39,941.23. Following the completion of the acquisition, the director now directly owns 368,792 shares in the company, valued at approximately $490,493.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lori A. Woods purchased 34,246 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was bought at an average cost of $1.46 per share, with a total value of $49,999.16. Following the acquisition, the director now owns 1,553,984 shares of the company’s stock, valued at $2,268,816.64. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 144,283 shares of company stock worth $200,849. Insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter valued at $15,511,000. Affinity Asset Advisors LLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter valued at $6,069,000. HighTower Advisors LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $314,000. Finally, Taylor & Morgan Wealth Management LLC grew its holdings in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 7.0 %

NYSE CATX opened at $1.20 on Friday. The company has a current ratio of 12.98, a quick ratio of 12.98 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a twelve month low of $0.21 and a twelve month high of $1.91.

Perspective Therapeutics (NYSE:CATXGet Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $0.33 million during the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. On average, analysts anticipate that Perspective Therapeutics will post -0.11 earnings per share for the current year.

About Perspective Therapeutics

(Get Free Report

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Read More

Analyst Recommendations for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.